44 completed, 41 recruiting, 30 terminated, 25 active not recruiting. 80 Phase 2, 68 Phase 1, 20 Phase 3, 1 Not applicable, 1 Phase 4.
Follow Exelixis: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Zanzalintinib in Unresectable and Progressive MPGGs Zanzalintinib - Pheochromocytoma, Paraganglioma | Phase 2 | Not yet recruiting | Dana-Farber Cancer Institute | 14 | 2027-01-09 | 2026-07-20 |
| Zanzalintinib and Pembrolizumab in First-Line Maintenance for Metastatic Squamous Non-Small Cell Lung Cancer (NSCLC) Carboplatin, Paclitaxel, Nab-paclitaxel - Squamous Non-Small Cell Lung Cancer (NSCLC) | Phase 2 | Not yet recruiting | Exelixis | 60 | 2026-12-15 | 2026-09-29 |
| Study of Tegavivint Plus Zanzalintinib in Patients With Advanced Hepatocellular Carcinoma Zanzalintinib, Tegavivint - Hepatocellular Carcinoma (HCC) | Phase 1 / Phase 2 | Not yet recruiting | University of Texas Southwestern Medical Center | 36 | 2026-12-01 | 2026-10-16 |
| Zanzalintinib for Advanced Urothelial Carcinoma Progressing After Prior Therapy Zanzalintinib - Advanced Urothelial Carcinoma | Phase 2 | Not yet recruiting | Guru Sonpavde | 44 | 2026-10-01 | 2026-09-02 |
| Study of Zanzalintinib in Children and Adolescents With Relapsed or Refractory Solid Tumors Zanzalintinib - Cancer, Pediatric Cancer | Phase 1 | Not yet recruiting | Exelixis | 18 | 2026-09-30 | 2026-08-19 |
| H&N NEO-COMBAT XL: Neoadjuvant XL-092 (Zanzalintinib) and Pembrolizumab (Keytruda) in Surgically Resectable, HPV Negative Oral Cavity Squamous Cell Carcinoma (OCSCC) XL092, Pembrolizumab - Oral Cavity Squamous Cell Carcinoma, Head and Neck Cancer | Phase 2 | Not yet recruiting | UNC Lineberger Comprehensive Cancer Center | 26 | 2026-09-01 | 2026-08-31 |
| Zanzalintinib Efficacy Post Pluvicto® in Chemotherapy Naïve Metastatic Castration Resistant Prostate Cancer Zanzalintinib - mCRPC (Metastatic Castration-resistant Prostate Cancer) | Phase 2 | Not yet recruiting | Stuthi Perimbeti | 30 | 2026-09-01 | 2026-06-03 |
| Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease Zanzalintinib, Pembrolizumab (+) Berahyaluronidase alfa, Placebo - Colorectal Cancer | Phase 3 | Recruiting | Exelixis | 600 | 2026-08-25 | 2026-09-21 |
| Zanzalintinib in Men With Aggressive Variant Prostate Cancer Zanzalintinib - Aggressive Variant Prostate Carcinoma | Phase 2 | Recruiting | Deepak Kilari | 30 | 2026-08-19 | 2026-08-28 |
| Long-Term Extension Study for Participants Previously Enrolled in an Exelixis-Sponsored Study Cabozantinib, Zanzalintinib, Atezolizumab - Cancer, Renal Cell Carcinoma (RCC) | Phase 3 | Enrolling by invitation | Exelixis | 5000 | 2026-07-30 | 2026-08-18 |
| Zanzalintinib for Metastatic Clear Cell Renal Cell Carcinoma With Bone Metastases Zanzalintinib, Investigator Choice of Bone Strengthening Agents (BSA), Non-Investigational Radiation Therapy (RT) - Clear Cell Renal Cell Cancer (ccRCC), Clear Cell Renal Carcinoma | Phase 2 | Recruiting | Kelly Fitzgerald, MD | 20 | 2026-06-10 | 2026-07-27 |
| A Study of Zanzalintinib in Participants With Recurrent or Progressive Meningioma Zanzalintinib - Meningioma | Phase 2 | Recruiting | Exelixis | 100 | 2026-05-21 | 2026-10-06 |
| Maintenance Zanzalintinib and Durvalumab in Participants With Advanced Hepatocellular Cancer Durvalumab, Zanzalintinib - Hepatocellular Carcinoma, Liver Cancer | Phase 2 | Not yet recruiting | Amit Mahipal | 16 | 2026-05-01 | 2026-05-05 |
| Phase 2 Trial of Zanzalintinib and Pembrolizumab in Select Subtypes of Advanced/Metastatic Soft-tissue Sarcoma Zanzalintinib, Pembrolizumab - Phase 2, Zanzalintinib | Phase 2 | Recruiting | M.D. Anderson Cancer Center | 20 | 2026-04-14 | 2026-08-20 |
| A Clinical Study of Belzutifan (MK-6482) and Zanzalintinib in People With Renal Cell Carcinoma (RCC) (LITESPARK-034/LS-034/MK-6482-034) Belzutifan, Zanzalintinib, Placebo - Carcinoma, Renal Cell | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 758 | 2026-04-09 | 2026-10-21 |
| Y-90 Radioembolization, Durvalumab, Tremelimumab, and Zanzalintinib for the Treatment of Unresectable and Locally-Advanced Hepatocellular Carcinoma Angiogram, Biopsy Procedure, Biospecimen Collection - Locally Advanced Hepatocellular Carcinoma, Stage III Hepatocellular Carcinoma AJCC v8 | Phase 2 | Not yet recruiting | OHSU Knight Cancer Institute | 40 | 2026-04-02 | 2026-04-06 |
| Trial of Zanzalintinib (XL092) in Combination With Immunotherapy in Patients Who Progress on Adjuvant Therapy in Clear Cell RCC XL092, Nivolumab - Advanced Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma | Phase 2 | Recruiting | Karie Runcie | 70 | 2026-03-13 | 2026-09-22 |
| Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study Cabozantinib, Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 1 | Recruiting | M.D. Anderson Cancer Center | 16 | 2026-02-12 | 2026-08-11 |
| Zanzalintinib in Combination With Ipilimumab and Nivolumab in Patients With Metastatic Soft Tissue Sarcoma Zanzalintinib, Ipilimumab, Nivolumab - Metastatic Soft-tissue Sarcoma | Phase 1 | Suspended | Washington University School of Medicine | 18 | 2026-01-05 | 2026-09-04 |
| Zanzalintinib Maintenance in Patients With High Grade Neuroendocrine Neoplasms (HG-NENs) Zanzalintinib - High Grade Neuroendocrine Neoplasms | Phase 2 | Recruiting | Washington University School of Medicine | 32 | 2025-12-09 | 2026-10-14 |
Showing 20 of 157. Sign in to see all of them.
Carcinoma, Renal Cell (26) · Neoplasms (22) · Carcinoma, Hepatocellular (14) · Carcinoma, Non-Small-Cell Lung (14) · Neoplasm Metastasis (12) · Colorectal Neoplasms (11) · Prostatic Neoplasms (10) · Brain Neoplasms (7) · Thyroid Neoplasms (7) · Breast Neoplasms (6) · Carcinoma, Transitional Cell (6) · Melanoma (6) · Neuroendocrine Tumors (6) · Sarcoma (6) · Pancreatic Neoplasms (5)
cabozantinib (81) · Nivolumab (28) · pembrolizumab (16) · Ipilimumab (12) · atezolizumab (10) · Prednisone (8) · BMS-833923 (4) · Sunitinib (4) · abiraterone (4) · durvalumab (4) · Abiraterone Acetate (3) · Docetaxel (3) · Radiotherapy (3) · belzutifan (3) · enzalutamide (3)
United States (150) · France (26) · United Kingdom (26) · Australia (24) · Spain (24) · Italy (22) · Germany (21) · Poland (21) · Belgium (20) · Canada (19) · South Korea (19) · Netherlands (17) · Argentina (13) · Austria (13) · Israel (13)
Deepak Kilari, MD (2) · Farshid Dayyani, MD, PhD (2) · Jennifer King, MD (2) · Mia Weiss, M.D. (2) · Nikolaos Trikalinos, M.D. (2) · Sara Tolaney, MD, MPH (2) · Umang Swami, MD (2) · Zeynep Eroglu, M.D. (2) · Adel Kardosh (1) · Alexander Drilon, MD (1) · Alexis Leal, MD (1)
PMID 33058158, PMID 21606412, PMID 23169517, PMID 23489023, PMID 23533264, PMID 23676418, PMID 24002501, PMID 24631409, PMID 24827131, PMID 25225437, PMID 26291023, PMID 26406150, PMID 26762579, PMID 27279544, PMID 27400947, PMID 27580889, PMID 27714541, PMID 27825636, PMID 28192597, PMID 28426123, PMID 28755607, PMID 28817373, PMID 29016998, PMID 29036345, PMID 29045520, PMID 29059635, PMID 29272162, PMID 29309249, PMID 29377755, PMID 29445030, PMID 29660005, PMID 29972759, PMID 30718102, PMID 31371341, PMID 31541381, PMID 31556911, PMID 31887537, PMID 32463152, PMID 32491932, PMID 32827353, PMID 32847838, PMID 33258687, PMID 33469991, PMID 33657295, PMID 33822328, PMID 33835977, PMID 34237250, PMID 34364385, PMID 34409776, PMID 34420143
P30CA138292 (4), 2018 (2), 2017 (1), 2023 (1), 2025 (1), N01CM00039 (1), N01CM00070 (1), N01CM00071 (1), N01CM00099 (1), P30CA016058 (1), P30CA046934 (1), P50CA265793 (1), UM1CA186705 (1)